> Pathogénie microbienne moléculaire - INSERM U389
• Summary
• Saga Shigella
• Objectives
• Genetics
• Cell Biology
• Inflammation
• Immunology
5 - Towards a one-dose, orally administered, genetically attenuated vaccine against shigellosis.
Philippe Sansonetti, Armelle Phalipon, Maria Mavris and Claude Parsot (PMM, Institut Pasteu).
Christine Sadorge (Centre de Recherche Clinique, Institut Pasteur).
Thomas Larry Hale (Walter Reed Army Institute of Research, Forrest Glen, Maryland).
David Lewis (Center for Experimental Vaccinology, London).
In 1994, in collaboration with the Walter Reed Army Institute of Research, the clinical testing of the live attenuated vaccine candidate strain of S.flexneri 2a SC602 (deltaicsA, deltaiuc iut) has been initiated. The attenuation and protective efficacy of SC602 against dysentery has been established, following a series of phase I and phase IIa/b studies carried out in adult volunteers in the US ( ). and a series of phase I studies carried out in different age sections in Bangladesh, both sponsored by the Walter Reed Army Institute of Research. These trials are currently pursued.
A phase I/II study is currently planned for a second vaccine candidate, the S.dysenteriae 1 strain SC599 deltaicsA, deltaent fep, deltastxA) ( ), The protocole of this study which is sponsored by the « Direction Générale à l’Armement » (DGA, Paris), has been established with the « Centre de Recherche Clinique de l’Institut Pasteur » (CRC). It will be carried out at the Center for Experimental Vaccinology at Saint George’s Hospital in London.
In the mean time, a complement of attenuated strains is being constructed in S.flexneri 3a an 6 and in S.sonnei with the aim to provide a « first generation » pentavalent vaccine.